Immunome Inc. — Director's Dealing 2025

Dec 23, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2025-12-22

Reporting Person: Barchas Isaac (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-22	Common Stock	S	371949	$21.72	Disposed	2042432	Indirect
2025-12-22	Common Stock	S	11251	$22.34	Disposed	2031181	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	92211	Direct

Footnotes

F1: The reported sale of these shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 23, 2024.

F2: The shares were sold as follows: 226,480 shares were sold by Arsenal Bridge Venture II, LLC ("ABV II") and 145,469 shares were sold by Arsenal Bridge Venture II-B, LLC ("ABV II-B" and collectively with ABV II, the "ABV Entities").

F3: The weighted average sale price for the transaction report was $21.72, and the range of prices were between $21.31 and $22.30, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F4: Following this transaction, ABV II and ABV II-B own 1,245,133 shares of Issuer common stock and 797,299 shares of Issuer common stock, respectively.

F5: Mr. Barchas is a co-founder and holder of a power of attorney with the ability to exercise voting and investment power over the shares held by ABV II and ABV II-B. Mr. Barchas disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares, if any. This report shall not be deemed an admission that Mr. Barchas is the beneficial owner of such shares.

F6: The shares were sold as follows: 6,851 shares were sold by ABV II and 4,400 shares were sold by ABV II-B.

F7: The weighted average sale price for the transaction report was $22.34, and the range of prices were between $22.31 and $22.38, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

F8: Following this transaction, ABV II and ABV II-B own 1,238,282 shares of Issuer common stock and 792,899 shares of Issuer common stock, respectively.

F9: Since the date of the Reporting Person's last ownership report, he transferred 29,469 shares of the Issuer's common stock to his ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.